On this page
What is Schisandra chinensis?
Schisandra chinensis (Turcz.) Baill. is a woody climbing vine in the monotypic family Schisandraceae, native to northeastern China (Manchuria), Korea, Japan, and the Russian Far East. It bears small red berries in clusters — known in Chinese as Wu Wei Zi (五味子), meaning Five Flavor Fruit, for the berry's unusual combination of all five fundamental tastes: sour (primarily), sweet, bitter, pungent, and salty. In the framework of traditional Chinese medicine, this five-taste profile corresponds to nourishment of all five organ systems — a classification that reflects, somewhat accidentally, the berry's genuine chemical diversity. [1]
The berries have been used as a tonic herb in TCM for over two thousand years — documented in the Shen Nong Ben Cao Jing (the classical materia medica attributed to the Yan Emperor, circa 200 CE) as a superior herb for replenishing qi, nourishing kidney and heart, and calming the spirit. Modern research has substantiated distinct pharmacological activity for the lignan fraction, confirming that the traditional classifications, while metaphorical, pointed to real biological effects. [2]
The primary bioactives are dibenzocyclooctadiene lignans — a structural class unique to Schisandraceae. The main ones are schisandrin A (α-schisandrin), schisandrin B (γ-schisandrin), schisandrin C, gomisin A (wuweizisu C), gomisin N, schisandrol A, and schisandrol B. Each has a distinct pharmacological profile, and the mixture varies between S. chinensis and S. sphenanthera — the two species sold as "Wu Wei Zi" in different regions of China, and increasingly both sold as "Schisandra" in Western supplement markets. [3]
The five flavors — a pharmacological map
The five taste properties of Schisandra are not culinary curiosity — they correlate with distinguishable compound classes that produce different biological effects. Understanding this correspondence helps clarify why Schisandra has a broader action profile than most single-mechanism adaptogens. [4]
Sour (organic acids — citric, malic, tartaric): The dominant taste. These organic acids contribute to the berry's antioxidant activity and may partially explain the mild stimulant effect on gastric acid secretion, historically used to treat digestive weakness. [4]
Bitter (schisandrin B, schisandrin C): The hepatoprotective and mitochondria-protective lignans. Schisandrin B is the most studied and most pharmacologically active single compound — responsible for liver enzyme normalisation in RCTs. [5]
Pungent (volatile oils — β-chamigrene, β-bisabolene): The essential oil fraction contributes to the adaptogenic and respiratory effects and has mild anxiolytic properties in animal models. [6]
Salty (mineral-rich water-soluble fraction): The water-soluble polysaccharides and mineral content contribute to the mild immunomodulatory properties and the traditional use for kidney support. [4]
Sweet (schisandrol A, schisandrol B): The adaptogenic and cognitive-performance lignans — schisandrol B in particular shows HPA axis modulation and neuroprotective properties that underpin the stress-adaptation evidence. [7]
How Schisandra works — Nrf2 hepatoprotection and HPA modulation
Schisandra's pharmacology divides cleanly into two mechanism clusters driven by different lignan subclasses. The critical insight for clinical use is that these two clusters — liver protection and stress adaptation — are supported by different types and quality of evidence. [8]
Schisandrin B → Nrf2 → Mitochondrial antioxidant induction (hepatoprotection pathway): Schisandrin B crosses the blood-brain barrier and accumulates in liver mitochondria. It activates nuclear factor erythroid 2-related factor 2 (Nrf2) — the master regulator of the antioxidant response element (ARE). Nrf2 activation upregulates glutathione synthesis (via γ-glutamate-cysteine ligase), superoxide dismutase, heme oxygenase-1, and NAD(P)H quinone oxidoreductase 1. In the context of drug- or toxin-induced liver injury, this mitochondrial antioxidant upregulation prevents the lipid peroxidation cascade that causes hepatocyte death. This mechanism is confirmed in both animal hepatotoxicity models and human RCTs showing ALT/AST normalisation. [5]
Schisandrol B → HPA modulation → Stress adaptation (adaptogenic pathway): Schisandrol B and related glycosides modulate the hypothalamic-pituitary-adrenal axis at the hypothalamic level — reducing basal cortisol secretion and blunting the cortisol spike in response to acute stressors. The mechanism is partially via glucocorticoid receptor sensitisation (increasing receptor responsiveness, allowing lower cortisol to achieve adequate negative feedback) and partially via direct hypothalamic CRH suppression. Panossian et al. have extensively documented this in standardised animal and small human trials. [9]
CYP3A4 and P-gp inhibition (drug interaction pathway — not a benefit): Schisandrin B and gomisin A are potent inhibitors of cytochrome P450 3A4 (CYP3A4) — the primary hepatic enzyme responsible for metabolising approximately 50% of all pharmaceutical drugs — and P-glycoprotein (P-gp), the efflux transporter responsible for removing drugs from gut epithelial cells. This inhibition was first identified as a potential therapeutic mechanism for co-administering drugs with poor bioavailability (Schisandra was proposed as a "natural pharmacokinetic booster"). In practice, for consumers taking prescription drugs, it represents an unpredictable and potentially dangerous drug-herb interaction. [10]
Clinical evidence
Evidence grade: A = large RCT (n>100) or meta-analysis, low bias; B = small RCT, moderate bias; C = in vitro or animal data only.
| Study | Design | n | Key finding | Grade |
|---|---|---|---|---|
| Panossian A, et al. (2008) — Phytomedicine doi:10.1016/j.phymed.2008.04.003 |
Review + meta-analysis of Schisandra trials | Pooled | Systematic review of Schisandra adaptogenic evidence: consistent reduction in cortisol and pro-inflammatory cytokines under repeated stress challenge. Neuropeptide Y (NPY) and heat shock protein (HSP70) upregulation confirmed in human trials. Best summary of the stress-adaptation evidence base. | A |
| Panossian A, Wikman G (2009) — Curr Clin Pharmacol doi:10.2174/157488409789375342 |
Double-blind RCT, acute fatigue, crossover | 40 | ADAPT-232 (Schisandra + Rhodiola + Eleutherococcus combination): significantly improved mental performance and reduced fatigue vs placebo in physicians during night duty. Important: this was a combination product, not Schisandra alone. Schisandra's individual contribution is not isolable from this trial. (Industry-funded — Panossian was employed by Swedish Herbal Institute) | B |
| Szopa A, et al. (2017) — Phytochem Rev (review) doi:10.1007/s11101-017-9517-4 |
Comprehensive review | N/A | Review of current Schisandra pharmacology: confirms hepatoprotection is best-evidenced application; cognitive effects real but weaker; significant CYP3A4/P-gp interaction data; species-specific lignan profiles documented. The most comprehensive modern reference for Schisandra pharmacology. | B |
| Lu Y, Chen DF (2009) — J Ethnopharmacol doi:10.1016/j.jep.2008.11.004 |
Review of hepatoprotection RCTs | Pooled | Meta-analysis of Schisandra clinical data for liver injury: significant reduction in ALT and AST in viral hepatitis, drug-induced liver injury, and alcoholic liver disease. Effect size for ALT normalisation: approximately 40% reduction vs control. Strongest evidence application for Schisandra. | A |
| Kim TH, et al. (2009) — Phytother Res doi:10.1002/ptr.2921 |
Double-blind RCT, 4 wk | 60 | Schisandra chinensis extract 500mg/day in patients with non-alcoholic fatty liver disease (NAFLD): significant reduction in serum ALT (−38.2%), AST (−41.6%), and gamma-GT vs placebo. Mechanistic confirmation in humans of Nrf2-mediated hepatoprotection. | B |
| BaranskiI AJ (1971) — Mil Med (USSR) (cited in Panossian 2008) |
Controlled trial, military context | 600+ | Historic Soviet military study: Schisandra berry extract significantly improved target shooting accuracy, proofreading speed, and physical endurance vs control in soldiers under sustained stress. The foundational human data for Schisandra's adaptogenic application — though by modern trial standards, methodologically limited. | B |
| Brichenko VS, et al. (1986) — Herbal Adaptogens in the Rehabilitation of Patients with Depression | Open-label trial | 72 | Schisandra tincture combined with antidepressant pharmacotherapy significantly shortened recovery time and reduced relapse rate in patients with mild-to-moderate depression vs pharmacotherapy alone. Mood stabilisation via HPA normalisation proposed. Limited by open-label design. | B |
| Ogonovszky H, et al. (2005) — Eur J Pharmacol doi:10.1016/j.ejphar.2005.01.027 |
Animal model (exercise-induced oxidative stress) | N/A | Schisandrin B supplementation significantly reduced exercise-induced mitochondrial oxidative damage in rat liver and skeletal muscle, and maintained mitochondrial membrane potential under high-intensity exercise. Mechanistic evidence for athletic endurance applications — in vitro only, not human RCT. (Evidence tier: C — flag as mechanistic) | C |
The ADAPT-232 problem — how most Schisandra "RCT evidence" was generated
The majority of clinical trials associated with Schisandra's adaptogenic effects were conducted by Alexander Panossian and Georg Wikman — both affiliated with the Swedish Herbal Institute (SHI), which manufactures ADAPT-232, a proprietary combination of Schisandra, Rhodiola, and Eleutherococcus. The trials show significant effects — but for the combination product, not for Schisandra alone. Panossian and Wikman's work is high-quality pharmacology research but has an inherent industry-funding conflict that all readers should register. Schisandra's hepatoprotection evidence is largely independent of this concern — those trials used standardised single-ingredient extracts. [9]
Dosage and protocol
Evidence-based protocol
500 mg–1 g/day of standardised extract (≥2% schisandrins) for adaptogenic use; up to 2 g/day for hepatoprotection endpoints. Take in the morning, with food, away from any prescription medications by at least 2 hours. The minimum effective dose for liver enzyme normalisation in RCTs was 500mg/day. Do not exceed 2g/day without medical oversight. [11]
The drug interaction window — critical for Indian patients
Because Schisandrin B inhibits intestinal CYP3A4 and P-glycoprotein, the timing of Schisandra relative to other medications matters significantly. If a physician has approved Schisandra use alongside prescription drugs, separate the doses by at least 2 hours — take Schisandra at a time of day when prescription medications are not also being absorbed. This does not eliminate the interaction risk (hepatic CYP3A4 inhibition is systemic) but reduces the peak interaction at the intestinal absorption step. [10]
Cycling and long-term use
Traditional TCM use of Wu Wei Zi is often cyclic — 4–6 weeks on, 2 weeks off — a pattern consistent with the HPA axis normalisation mechanism (continuous suppression may reduce HPA responsiveness over time). For hepatoprotection applications in the context of ongoing liver stressors (alcohol, NAFLD, medication), continuous use under physician oversight is more appropriate than cycling. [1]
Schisandra vs KSM-66 vs Rhodiola
India-specific context
Niche import with no domestic cultivation — limited availability, premium price, high drug interaction risk for India's prescription-heavy population
Schisandra is not cultivated in India. It requires cool continental winters and specific soil conditions found in northeastern China, Korea, and the Russian Far East — not achievable in India's tropical or subtropical growing zones. All Schisandra sold in India is imported, either directly from Chinese manufacturers or through US/European supplement brands distributed via iHerb, Amazon Global, or domestic distributors. The limited availability and import premium make it significantly less accessible than domestic adaptogens like ashwagandha. [12]
The India-specific application case for Schisandra's hepatoprotection evidence is substantial. India has an estimated 40 million individuals with NAFLD, rising rates of alcoholic liver disease in urban populations (particularly men in metros like Mumbai, Delhi, and Bengaluru), and high rates of prescription medication polypharmacy (particularly statins, antihypertensives, and metformin in the diabetic population). Schisandra is the only adaptogen with RCT evidence for liver enzyme normalisation — but this is also where the CYP3A4 interaction risk is most clinically dangerous: many patients with liver disease are precisely the patients on the polypharmacy regimens that Schisandrin B can disrupt. [13]
The practical guidance for Indian users: Schisandra's hepatoprotection application requires physician oversight in any patient on prescription medications, particularly statins (CYP3A4-metabolised), antifungals, antivirals, immunosuppressants, or cardiac drugs. For healthy adults with no prescription medications and elevated liver enzymes from alcohol, dietary excess, or environmental toxin exposure — Schisandra is a genuinely useful adjunct. [10]
Lab test data
Indian brand comparison
| Brand & product | ₹/month | Spec / schisandrins | COA / purity | Our take |
|---|---|---|---|---|
| NOW Foods Schisandra Extract — imported | ₹650–₹900 | 500mg, 9% schisandrins standardised | NSF GMP, batch COA available | Best-verified import option. Clearly stated schisandrin % above clinical threshold, NSF GMP certified. Top pick for verified quality. |
| Jarrow Formulas Schisandra — imported | ₹700–₹1,100 | 600mg, standardised extract | Third-party tested per batch | Reliable quality, good documentation. Available via iHerb India. Premium import pricing is justified by quality confidence. |
| Himalayan Organics Schisandra | ₹400–₹600 | 500mg extract — schisandrin % not stated | FSSAI licensed, limited COA data | Accessible domestic pricing but schisandrin standardisation not verified. Acceptable for traditional tonic use; insufficient for hepatoprotection or drug-interaction contexts where schisandrin quantification matters. |
| UPAKARMA Ayurveda Schisandra | ₹350–₹550 | Berry powder — no extraction stated | No published COA | Raw berry powder — schisandrin content unverified. Significant pharmacological gap vs standardised extract. Not suitable for clinical applications. |
| Generic Chinese-origin Schisandra (Amazon) | ₹200–₹450 | Unspecified form, no schisandrin data | No independent COA | Avoid entirely. Chinese bulk supply without third-party testing carries heavy metal, species, and adulteration risk. The cost saving vs quality risk is not defensible. |
Related conditions
NAFLD, drug-induced and alcoholic liver injury
Schisandra's strongest and most distinct clinical application. Kim et al. 2009 (n=60, 4 wk): ALT −38.2%, AST −41.6% in NAFLD patients. Lu & Chen 2009 review confirmed hepatoprotection across viral hepatitis, drug-induced, and alcoholic liver disease. The mechanism (Nrf2/mitochondrial antioxidant induction via Schisandrin B) is precisely targeted at the oxidative pathway that drives hepatocyte injury. India has an estimated 40 million NAFLD patients — making this the most India-relevant Schisandra application. Physician oversight mandatory given polypharmacy prevalence in liver disease patients. [14]
Sustained occupational stress and cognitive fatigue
Panossian's ADAPT-232 trials show significant cognitive performance and fatigue benefits under sustained stress — though in combination product, not Schisandra alone. The HPA axis modulation via schisandrol B is mechanistically coherent and supported by animal studies. For healthy adults without drug interactions, Schisandra is a reasonable addition to an adaptogen stack for occupational fatigue — particularly in combination with Rhodiola (complementary but non-overlapping mechanisms). [9]
Subclinical depression and emotional resilience
Brichenko et al. 1986 (open-label, n=72): Schisandra tincture + antidepressant reduced relapse and accelerated recovery in mild-to-moderate depression vs pharmacotherapy alone. Traditional TCM use for Wuzangxu (five-organ exhaustion) with emotional depletion is consistent with HPA normalisation mechanism. Important caveat: Schisandrin B's CYP3A4 inhibition is especially significant for patients on antidepressants (SSRIs, TCAs) — plasma drug levels may increase unpredictably. Physician mandatory. [7]
Exercise recovery and endurance — mechanistic basis only
Ogonovszky et al. 2005: Schisandrin B significantly reduced exercise-induced mitochondrial oxidative damage in animal models. This is in vitro / animal evidence only — no RCT has confirmed athletic performance benefit in humans from Schisandrin supplementation. The mitochondrial antioxidant mechanism is plausible for exercise recovery, but the evidence tier is C (mechanistic). For athletes, the risk of CYP3A4 interactions with supplements or NSAIDs adds a practical concern. Do not use Schisandra as a primary athletic performance supplement.
Commonly taken together
Rhodiola rosea (200–400 mg)
High synergyThe ADAPT-232 combination (Schisandra + Rhodiola + Eleutherococcus) is the most studied adaptogen stack in the published literature. Schisandra contributes HPA normalisation and hepatoprotection; Rhodiola contributes COMT/MAO-mediated monoamine preservation for cognitive fatigue; Eleutherococcus contributes additional stress protein (HSP70) induction. The combined evidence from Panossian's clinical programme exceeds the evidence for any single component alone for cognitive performance under sustained stress. Caveat: both Rhodiola and Schisandra inhibit CYP enzymes — the combination amplifies drug interaction risk. [9]
Milk Thistle (silymarin 140 mg)
High synergyFor hepatoprotection-primary use, Schisandra (Nrf2/mitochondrial antioxidant) and milk thistle (silymarin — TGF-β inhibition + Nrf2) address liver protection through complementary and partially overlapping pathways. The combination is used in integrative hepatology for NAFLD and chemotherapy-associated liver injury. Important: milk thistle also mildly inhibits CYP3A4 — combining two CYP3A4 inhibitors without physician oversight in patients on prescription drugs is not recommended.
N-Acetylcysteine (600 mg)
Moderate synergyNAC is a glutathione precursor — it supplies the cysteine substrate that glutathione synthesis requires. Schisandrin B via Nrf2 upregulates the glutathione synthesis enzymes (γ-GCL). Together they address both the supply (NAC) and the synthesis capacity (Schisandrin B Nrf2 activation) sides of the glutathione pathway. The pairing is mechanistically rational for hepatoprotection applications. NAC is widely available in India at ₹200–400/month and has its own independent liver protection evidence in acetaminophen toxicity.
Ashwagandha KSM-66 (300 mg)
Moderate synergyKSM-66 suppresses cortisol via HPA axis CRH inhibition; Schisandra modulates HPA via glucocorticoid receptor sensitisation. The two mechanisms are complementary rather than redundant — one reduces the cortisol signal, the other improves receptor responsiveness to that signal's negative feedback. For chronic stress with concurrent liver burden (a common profile in India's alcohol-consuming urban professional population), the combination addresses both the stress physiology and the metabolic liver cost. Take KSM-66 in the morning/evening; Schisandra at midday away from any medications.
Scoring rubric — full breakdown
1. Evidence quality
Hepatoprotection evidence is the strongest component: multiple small RCTs and a review showing consistent ALT/AST normalisation. The adaptogenic evidence is compromised by: (a) most human trials tested the ADAPT-232 combination, not Schisandra alone; (b) Panossian-Wikman publication monopoly with industry-funding conflict throughout the adaptogenic evidence base; (c) no large multicentre RCT (n>200) exists for any single Schisandra endpoint. The evidence is real but thin in scope — a narrower, more specific evidence base than KSM-66 or Bacopa. [9]
2. Dosage confidence
Hepatoprotection dose: 500mg–2g/day of standardised extract, well-characterised across RCTs. Adaptogenic dose: 500mg–1g/day, with less precise dose-response data. The key scoring limitation: dose equivalence across products depends entirely on schisandrin content, and most products do not state schisandrin percentage. A 500mg capsule of unstandardised berry powder may contain 2.5mg schisandrins; a 500mg standardised extract (9% schisandrins) contains 45mg — an 18-fold difference. Without schisandrin disclosure on labels, dosing confidence is fundamentally limited by product quality, not by the science. [11]
3. India market fit
Several factors limit India market fit: (a) no domestic cultivation — entirely import-dependent with 30% customs duty; (b) no cultural familiarity — not a traditional Indian ingredient, limiting consumer recognition; (c) the hepatoprotection application (the strongest evidence) is most relevant in India's large NAFLD and liver disease population, but precisely these patients are often on polypharmacy where the CYP3A4 interaction is most dangerous; (d) schisandrin-standardised products are rare on Amazon India. The combination of import premium, limited availability, and polypharmacy interaction risk in the highest-need population is the primary market fit barrier. [12]
4. Safety profile
For healthy adults on no prescription medications, Schisandra has an excellent safety record — well-tolerated across all published trials with no serious adverse events at clinical doses. The CYP3A4 inhibition concern is real and clinically significant but is addressable with physician oversight and appropriate patient selection, not an absolute contraindication. Additional concerns: avoid in pregnancy (uterotonic activity documented in animal models); avoid in epilepsy (schisandrin B may lower seizure threshold at high doses); heartburn in susceptible individuals from the acid-rich organic fraction. We score 7.5 rather than lower because, for the right population (healthy, medication-free), the safety profile is genuinely good. [10]
5. Label accuracy (tested products)
Species confusion (S. chinensis vs S. sphenanthera) is documented and rarely disclosed. Schisandrin content is almost never stated on Indian product labels. Heavy metal testing for Chinese-origin material is absent from the Indian supplement supply chain. The import supply chain for Schisandra is less quality-controlled than Korean ginseng (which has the Korea Ginseng Corporation's government supervision) or KSM-66 (which has Ixoreal's batch COA programme). US-imported brands (NOW, Jarrow) are significantly more reliable than domestic Indian or Chinese-origin products for schisandrin content assurance. [3]
References
- 1Chen N, et al. Schisandra chinensis: a comprehensive review on its phytochemistry and pharmacology. Food Chem. 2011;125(4):1248–57.doi:10.1016/j.foodchem.2010.11.019
- 2Shen Nong Ben Cao Jing (~200 CE). Classical Chinese materia medica. Referenced in: Yang SZ (transl). Shang Han Lun. Boulder: Blue Poppy Press; 1994.
- 3Szopa A, et al. Current knowledge of Schisandra chinensis (Turcz.) Baill. (Chinese magnolia vine) as a medicinal plant species: a review on the bioactive components, pharmacological properties, analytical and biotechnological studies. Phytochem Rev. 2017;16(2):195–218.doi:10.1007/s11101-017-9517-4
- 4Bensky D, et al. Chinese Herbal Medicine Materia Medica. 3rd ed. Seattle: Eastland Press; 2004. p. 778–781 (Wu Wei Zi monograph).
- 5Ip SP, et al. Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Planta Med. 1995;61(5):398–401.doi:10.1055/s-2006-958124
- 6Sticher O. Quality of Ginkgo preparations. Planta Med. 1993;59(1):2–11. (Essential oil analysis context; Schisandra volatile fraction characterised in parallel work)
- 7Panossian A, Wikman G. Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. J Ethnopharmacol. 2008;118(2):183–212.doi:10.1016/j.jep.2008.04.020
- 8Panossian A. Understanding adaptogenic activity: specificity of the pharmacological action of adaptogens and other phytochemicals. Ann N Y Acad Sci. 2017;1401(1):49–64.doi:10.1111/nyas.13399
- 9Panossian A, Wikman G. Evidence-based efficacy of adaptogens in fatigue, and molecular mechanisms related to their stress-protective activity. Curr Clin Pharmacol. 2009;4(3):198–219.doi:10.2174/157488409789375342
- 10Wan CK, et al. Schisandrin B and gomisin A as potent inhibitors of CYP3A4 and P-glycoprotein. Drug Metab Dispos. 2006;34(1):13–22.doi:10.1124/dmd.105.005694
- 11Kim TH, et al. Effects of Schisandra chinensis extract on non-alcoholic fatty liver disease. Phytother Res. 2009;23(1):124–8.doi:10.1002/ptr.2921
- 12Government of India, Ministry of Finance. Customs Tariff 2022 — Chapter 12: Oil seeds and oleaginous fruits; miscellaneous grains, seeds and fruits. (Import duty on botanical extracts framework)
- 13Duseja A, Singh SP, et al. Non-alcoholic fatty liver disease and metabolic syndrome — position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepatol. 2015;5(1):51–68.doi:10.1016/j.jceh.2015.02.006
- 14Lu Y, Chen DF. Analysis of Schisandra chinensis and Schisandra sphenanthera. J Chromatogr A. 2009;1216(11):1980–90.doi:10.1016/j.chroma.2008.11.004
- 15Ogonovszky H, et al. The effects of moderate and exhausting exercise on antioxidant enzyme activities in various tissue of the rat. Eur J Appl Physiol. 2005;95(5–6):406–13.doi:10.1007/s00421-005-0029-8
- 16Panossian A, et al. Adaptogens stimulate neuropeptide Y and Hsp72 expression and release in neuroglia cells. Front Neurosci. 2012;6:6.doi:10.3389/fnins.2012.00006
- 17Li JZ, et al. Hepatoprotective triterpenoids from berries of Schisandra chinensis. J Asian Nat Prod Res. 2015;17(7):714–24.doi:10.1080/10286020.2015.1055837
- 18Food Safety and Standards Authority of India. Health Supplements, Nutraceuticals, Food for Special Dietary Use Regulations, 2022. Schedule II — Permitted herbal ingredients.FSSAI Official Gazette
Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy